Corbyn Investment Management Inc. MD Sells 1,824 Shares of Kenvue Inc. (NYSE:KVUE)

Corbyn Investment Management Inc. MD decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,279 shares of the company’s stock after selling 1,824 shares during the period. Kenvue makes up 1.3% of Corbyn Investment Management Inc. MD’s holdings, making the stock its 26th biggest position. Corbyn Investment Management Inc. MD’s holdings in Kenvue were worth $3,077,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its position in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the period. Mather Group LLC. bought a new position in shares of Kenvue in the first quarter worth $28,000. Riverview Trust Co bought a new position in shares of Kenvue in the first quarter worth $33,000. MV Capital Management Inc. increased its position in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after purchasing an additional 642 shares during the period. Finally, Salomon & Ludwin LLC bought a new position in shares of Kenvue in the first quarter worth $33,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $22.86 on Friday. The business’s 50-day moving average price is $19.92 and its 200-day moving average price is $19.67. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.00. The firm has a market capitalization of $43.77 billion, a price-to-earnings ratio of 29.31, a PEG ratio of 2.76 and a beta of 1.40. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business’s revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the firm posted $0.32 earnings per share. Equities research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were paid a $0.205 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.59%. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s payout ratio is currently 105.13%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on KVUE shares. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Wednesday, August 7th. UBS Group raised their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Citigroup reduced their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft raised their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. raised their price objective on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $21.44.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.